

35 U.S.C. §111 APPLICATION
Continuation
Page 1 of 3

08 425022

LST
7/28/95
#2/1

Case No. 5400/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of

Stephen R. Bertenshaw and John J. Talley

Anticipated Classification of This Application: Class
Subclass

THE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith for filing is a continuation application under 35 U.S.C. §111, of pending prior Application Serial Number US94/00466, designating the United States, filed on January 14, 1994 of Stephen R. Bertenshaw, Paul W. Collins, Thomas D. Penning, David B. Reitz, Roland S. Rogers and John J. Talley, entitled NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTI-INFLAMMATORY AGENTS

- Enclosed is a copy of the prior application. I hereby verify that the attached papers are a true copy of said prior application as originally filed on January 14, 1994.
- Cancel in this application, original Claims 2-34 of the prior application before calculating the filing fee. (At least one original, independent claim must be retained for filing purposes)
- Amend the specification by inserting before the first line the sentence: --Related Case
This is a continuation of International Application PCT/US94/00466, with an international filing date of January 14, 1994. --

A preliminary amendment is enclosed.

The filing fee is calculated below:

Basic Filing Fee [37 CFR 1.16(a)]				\$730.00	
Additional Filing Fee [37 CFR 1.16(b), (c)]					
Claims	No. Filed	No. Extra	Rate		
Independent	5 - 3 =	2	X \$76.00 =	\$152.00	
Total	13 - 20 =	0	X \$22.00 =	\$ 0.00	
				\$882.00	
TOTAL FEE:					

Case No. 5400/2

- A triplicate copy of this transmittal paper is enclosed.
- Please charge the above calculated total fee to my Deposit Account No. 19-1025.
- The Commissioner is hereby authorized and requested to charge any fees in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025 [37 CFR 1.25(b)].

NOTE: THIS AUTHORIZATION DOES NOT
INCLUDE FEES REQUIRED UNDER 37
CFR 1.18

- Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. ANOTHER DUPLICATE COPY OF THIS SHEET IS ENCLOSED FOR FILING IN THE PRIOR APPLICATION FILE.
- New formal drawings are enclosed.
- Priority of International Application _____, filed on _____ is claimed under 35 U.S.C. 119.
- The certified copy of the priority application has been filed in prior Application Serial No. _____, filed _____.
- The Power of Attorney in the prior application is to G.D. Searle & Co., namely, Joseph W. Bulock, Registration Number 37,103.
- The PCT power appears in the original papers in the prior application.
- The U.S. Declaration and Power of Attorney for the subject application is enclosed.
- The U.S. Assignment along with Assignment Cover will be mailed under separate cover.
- Address all future communications to:

G.D. Searle & Co.
Corporate Patent Department
P.O. Box 5110
Chicago, Illinois 60680

35 U.S.C. §111 APPLICATION
Continuation
Page 3 of 3

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 13 April 1995

Address of Signer:

Searle Research & Development
c/o Monsanto Company - O4E
800 Lindbergh Boulevard North
St. Louis, Missouri 63167

Joseph W. Bullock
Joseph W. Bullock
Attorney for Applicants
Registration No. 37,103
314-694-9094 (St. Louis)